UY33872A - Uso de análogos de glucagón acilados - Google Patents

Uso de análogos de glucagón acilados

Info

Publication number
UY33872A
UY33872A UY0001033872A UY33872A UY33872A UY 33872 A UY33872 A UY 33872A UY 0001033872 A UY0001033872 A UY 0001033872A UY 33872 A UY33872 A UY 33872A UY 33872 A UY33872 A UY 33872A
Authority
UY
Uruguay
Prior art keywords
acilated
glucagon analogs
glucagon
analogs
image
Prior art date
Application number
UY0001033872A
Other languages
English (en)
Inventor
Fosgerau Keld
Riber Ditte
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of UY33872A publication Critical patent/UY33872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a procedimientos para tratar trastornos metabólicos, incluyendo diabetes, mediante el uso de una combinación de un análogo de glucagón acilado y un análogo de insulina. La invención también se refiere a un kit que incluye un análogo de glucagón acilado y un análogo de insulina.
UY0001033872A 2011-01-20 2012-01-20 Uso de análogos de glucagón acilados UY33872A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161434698P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
UY33872A true UY33872A (es) 2012-08-31

Family

ID=45607302

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033872A UY33872A (es) 2011-01-20 2012-01-20 Uso de análogos de glucagón acilados

Country Status (20)

Country Link
US (2) US20140011733A1 (es)
EP (1) EP2665487A1 (es)
JP (1) JP2014504597A (es)
KR (1) KR20140043709A (es)
CN (1) CN103491975B (es)
AR (1) AR085086A1 (es)
AU (1) AU2012208349A1 (es)
BR (1) BR112013018269A2 (es)
CA (1) CA2824397A1 (es)
CL (1) CL2013002085A1 (es)
CO (1) CO6761400A2 (es)
EA (1) EA201390796A1 (es)
MA (1) MA34913B1 (es)
MX (1) MX2013008005A (es)
PE (1) PE20140969A1 (es)
SG (1) SG192038A1 (es)
TN (1) TN2013000251A1 (es)
TW (1) TW201247702A (es)
UY (1) UY33872A (es)
WO (1) WO2012098462A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AP2011005774A0 (en) 2008-12-15 2011-06-30 Zealand Pharma As Glucagon analogues.
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
GEP20146056B (en) 2009-07-13 2014-03-10 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
NZ604208A (en) 2010-06-24 2014-10-31 Zealand Pharma As Glucagon analogues
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
WO2014016300A1 (en) 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AU2014241743B2 (en) * 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
DK3283507T3 (da) * 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
US20190175744A1 (en) * 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
US11058775B2 (en) 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
CN110546161B (zh) 2016-09-23 2024-01-26 韩美药品股份有限公司 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途
CN110536899B (zh) 2017-03-23 2023-12-12 韩美药品株式会社 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
MX2021007124A (es) * 2018-12-21 2021-08-11 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que incluye insulina y glucagon.
US20230293639A1 (en) * 2020-06-11 2023-09-21 Abvance Therapeutics, Inc. Systems, devices, compositions, and methods for treating diabetes
KR20240099485A (ko) * 2021-11-19 2024-06-28 메드샤인 디스커버리 아이엔씨. 스테이플화 펩타이드 및 이의 용도

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
UA45321C2 (uk) 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
RU2214419C2 (ru) 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
ES2239364T3 (es) 1996-09-09 2005-09-16 Zealand Pharma A/S Sintesis de peptidos en fase solida.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
RU2001128068A (ru) 1999-03-17 2004-02-20 Ново Нордиск А/С (DK) Способ ацилирования пептидов и новые ацилирующие агенты
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
CA2468100A1 (en) 2001-12-20 2003-07-03 Eli Lilly And Company Insulin molecule having protracted time action
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1620465A2 (en) 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
RU2010147076A (ru) 2008-04-22 2012-05-27 Кейз Вестерн Ризев Юнивесити (Us) Аналоги инсулина специфичные к изоформам
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2009155258A2 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2727161A1 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
BRPI0916560A2 (pt) 2008-07-31 2015-11-10 Univ Case Western Reserve análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
AP2011005774A0 (en) * 2008-12-15 2011-06-30 Zealand Pharma As Glucagon analogues.
JP5635532B2 (ja) * 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070253A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
CN102292347A (zh) * 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
GEP20146056B (en) * 2009-07-13 2014-03-10 Zealand Pharma As Acylated glucagon analogues
EA023925B1 (ru) * 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
TW201247702A (en) 2012-12-01
NZ612719A (en) 2015-05-29
TN2013000251A1 (en) 2014-11-10
JP2014504597A (ja) 2014-02-24
MA34913B1 (fr) 2014-02-01
MX2013008005A (es) 2013-08-21
EA201390796A1 (ru) 2014-07-30
AU2012208349A1 (en) 2013-07-18
SG192038A1 (en) 2013-08-30
US20160000883A1 (en) 2016-01-07
EP2665487A1 (en) 2013-11-27
CO6761400A2 (es) 2013-09-30
CL2013002085A1 (es) 2013-12-06
BR112013018269A2 (pt) 2017-06-06
AR085086A1 (es) 2013-09-11
WO2012098462A1 (en) 2012-07-26
CA2824397A1 (en) 2012-07-26
CN103491975B (zh) 2016-05-11
US20140011733A1 (en) 2014-01-09
CN103491975A (zh) 2014-01-01
PE20140969A1 (es) 2014-07-24
KR20140043709A (ko) 2014-04-10

Similar Documents

Publication Publication Date Title
UY33872A (es) Uso de análogos de glucagón acilados
BR112014015681A2 (pt) análogos de glucagon
BR112015005783A8 (pt) análogos de glucagon
BR112015001451A2 (pt) análogos de glucagon
BR112013024076A2 (pt) análogos de glucagon
UY34365A (es) Compuestos heterociclicos
BR112016003454A2 (pt) Uso de composto de metil bardoxolona
DK3410725T3 (da) Referencebilledsignalering
BR112014008590A2 (pt) métodos de uso de antagonistas de scd1
BR112014023200A2 (pt) uso de uma composição
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
SMT201600410B (it) Modulatori diidropirazolici di gpr40
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
UY33957A (es) Moduladores de los receptores de hormonas nucleares
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay
UY33906A (es) Composiciones herbicidas que comprenden topramezona
UY33909A (es) Metodo para producir fibra de lignina
BR112013024784A2 (pt) análogos de peptídeos de ação prolongada
BR112014003027A2 (pt) formulação herbicida melhorada
BR112014013660A2 (pt) uso de uma partícula
CO6801700A2 (es) Uso demetilhidroxietilcvelulosacomo aditivo de cemento
EP2672926A4 (en) RESTORATION OF ACCOMMODATION BY FILLING THE CRYSTALLINE
BR112013018812A2 (pt) projetor

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200422